Gene therapy for Parkinson's: will it last? new study tracks 6 patients over time
NCT ID NCT07629115
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study checks the long-term safety and lasting effects of a gene therapy called IPS101A in 6 people with severe Parkinson's disease who already received it in an earlier trial. Researchers will monitor side effects and measure changes in movement symptoms over time. The goal is to see if a one-time gene therapy can safely control Parkinson's for years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPS101A gene therapy
What this could lead to
If successful, this could show that a single dose of gene therapy safely controls Parkinson's symptoms for years, reducing the need for daily medications.
What could go wrong
This is a very small follow-up study with only 6 people, so results may not apply to everyone. It is also early-stage, so long-term risks or loss of effect are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Severance Hospital
RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••